Read this Release on Our Investor Relations Website | PDF Version -- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4…
NeuroPace Inc.March 5, 2024
Groundbreaking NAUTILUS study will evaluate the safety and effectiveness of the RNS System to treat generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
NeuroPace Inc.October 11, 2022
RESPONSE Study first to evaluate the effectiveness of brain-responsive neuromodulation to treat focal epilepsy in patients 12 through 17 MOUNTAIN VIEW, Calif. — May 4,…
NeuroPace Inc.May 4, 2022
IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
NeuroPace Inc.November 10, 2021
New Online Physician Portal Integrates RNS System’s EEG Data with Patient Seizure Diary App to Help Doctors Provide More Comprehensive, Data-Driven Care for Epilepsy Patients…
NeuroPace Inc.August 4, 2021
Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif. — June 30, 2021…
NeuroPace Inc.June 30, 2021
Company plans to pursue indication expansion to broaden access to include patients with second most common type of epilepsy. MOUNTAIN VIEW, Calif. – March 31,…
RobbyMarch 31, 2021
Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif. – August 31, 2020 – NeuroPace,…
NeuroPace Inc.August 31, 2020
Personalized, data-driven treatment for refractory focal epilepsy demonstrates unprecedented real-world results and exceptional long-term clinical data MOUNTAIN VIEW, Calif. – July 27, 2020 – NeuroPace,…
NeuroPace Inc.July 29, 2020
